The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...

Dr Mohan discusses with Dr Nadeem, Dr Mann, and Nurse Distaso the key factors for referring patients from community centers to academic institutions for bispecific therapy and strategies for ...

The influenza A virus genome consists of eight segments of single-stranded, negative-sense viral RNA, which encode multiple ...

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

The year 2015 marked the inception of Sanyou Bio's technological journey, laying the foundation for its core technology platform. The R&D team devoted itself to the development of display vectors, ...

Antibody therapies are a type of biologic. They are typically monoclonal antibodies selected to bind to a particular protein (often a cell-surface protein), and produced using recombinant DNA ...

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y ...

What are the most common logistical challenges you encounter when implementing bispecific therapies in both academic and community settings? (Dr Allan) ...